KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced ...

The iShares Core S&P Mid-Cap ETF is great for broad stock market exposure. The Vanguard Mid-Cap Value ETF targets more undervalued stocks. The Invesco S&P MidCap Quality ETF focuses on stocks with ...

An announcement from Cingulate Inc ( (CING)) is now available. Cingulate Inc. announced that as of December 15, 2025, Shane Schaffer has been reinstated as Chief Executive Officer after being placed ...

It would be slightly ridiculous to reinvent your entire home every time a new interiors trend rolled around, but taking a closer look at what’s poised to define 2026 certainly has its merits. It can ...

A few trends saw a symbiotic relationship with the structure. Raw concrete walls and ceilings are as much a part of the building's infrastructure as the aesthetic interior finish. So are exposed ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Kansas City, Kansas ...

Shane Schaffer, the CEO of Cingulate, was charged with aggravated domestic battery in Johnson County District Court earlier this month. Schaffer was placed on leave, and his photo and bio have been ...

Cingulate submitted its New Drug Application (NDA) for CTx-1301 to the FDA, targeting the ADHD market, with an NDA acceptance decision expected in late 2025. Operating expenses increased for the three ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Cingulate Inc. placed its CEO on ...